eNauka - pregled

Pregled prema Projekat Celltrion Inc.

Prikaz rezultata 1 do 6 od 6
GodinaNaslovAutor(i)Tip rezultataMp-kat.
20221-year follow-up of a phase III study to compare efficacy and safety of a bevacizumab biosimilar, CT-P16, and reference bevacizumab as first-line treatment for metastatic or recurrent non-squamous non-small cell lung cancerVerschraegen, Claire; Andric, Zoran G  ; ...; (broj, koautora 20)Konferencijski rad
Mp kategorija će biti prikazana naknadno.
20243-year follow-up of a phase III study to compare efficacy and safety of a bevacizumab biosimilar, CT-P16, and reference bevacizumab as first-line treatment for metastatic or recurrent non-squamous non-small cell lung cancerVerschraegen, C; Andric, Zoran G  ; Moiseenko, FV; Makharadze, T; Oleksiienko, A; Ruiz, EP Yanez; Kim, SH; Ahn, K; Park, TH; Ju, HA;
Baek, EH; Kwon, S; Lee, SJ; Chang, I; Kim, SH; Kim, HA; Lee, E; Ohe, Y;
Konferencijski rad
Mp kategorija će biti prikazana naknadno.
2022Candidate Bevacizumab Biosimilar CT-P16 versus European Union Reference Bevacizumab in Patients with Metastatic or Recurrent Non-Small Cell Lung Cancer: A Randomized Controlled TrialVerschraegen, Claire; Andric, Zoran G  ; Moiseenko, Fedor; Makharadze, Tamta; Shevnya, Sergii; Oleksiienko, Alona; Ruiz, Eduardo Yanez; Kim, SungHyun; Ahn, KeumYoung; Park, TaeHong;
Park, Sijin; Ju, Hana; Ohe, Yuichiro;
Naučni članak
21aM21a - Vodeći međunarodni časopis kategorije M21a
2025Long-term results of a randomized controlled trial of biosimilar CT-P16 and reference bevacizumab in patients with metastatic or recurrent non-small cell lung cancerAndric, Zoran  ; ...; (broj, koautora 16)Naučni članak
22M22 - Međunarodni časopis kategorije M22
2025Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn's disease and ulcerative colitis: 2-year results from open-label extensions of two randomized controlled trials (LIBERTY)Colombel, Jean Frederic; ...; Sreckovic, Slobodan; ...; (broj, koautora 33)Naučni članak
21aM21a - Vodeći međunarodni časopis kategorije M21a
2024Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY)Hanauer, Stephen B; ...; Sreckovic, Slobodan; ...; (broj, koautora 33)Naučni članak
21a+M21a+ - Vodeći međunarodni časopis kategorije M21a+